ATE473756T1 - Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs - Google Patents

Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs

Info

Publication number
ATE473756T1
ATE473756T1 AT06812748T AT06812748T ATE473756T1 AT E473756 T1 ATE473756 T1 AT E473756T1 AT 06812748 T AT06812748 T AT 06812748T AT 06812748 T AT06812748 T AT 06812748T AT E473756 T1 ATE473756 T1 AT E473756T1
Authority
AT
Austria
Prior art keywords
treatment
prevention
pharmaceutical composition
glycoproteins
polypeptides
Prior art date
Application number
AT06812748T
Other languages
English (en)
Inventor
Bennink Coelingh
Visser Monique
Original Assignee
Pantarhei Bioscience Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantarhei Bioscience Bv filed Critical Pantarhei Bioscience Bv
Application granted granted Critical
Publication of ATE473756T1 publication Critical patent/ATE473756T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06812748T 2005-11-16 2006-11-16 Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs ATE473756T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73687705P 2005-11-16 2005-11-16
EP05110819 2005-11-16
PCT/NL2006/050289 WO2007058536A1 (en) 2005-11-16 2006-11-16 Pharmaceutical composition for treating or preventing ovarian cancer

Publications (1)

Publication Number Publication Date
ATE473756T1 true ATE473756T1 (de) 2010-07-15

Family

ID=37686152

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06812748T ATE473756T1 (de) 2005-11-16 2006-11-16 Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs

Country Status (8)

Country Link
US (1) US7968514B2 (de)
EP (1) EP1951283B1 (de)
CN (1) CN101365473B (de)
AT (1) ATE473756T1 (de)
CA (1) CA2630175C (de)
DE (1) DE602006015508D1 (de)
PL (1) PL1951283T3 (de)
WO (1) WO2007058536A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9295720B2 (en) 2010-08-27 2016-03-29 Pantarhei Bioscience B.V. Immunotherapeutic method for treating prostate cancer
WO2013040071A2 (en) * 2011-09-15 2013-03-21 University Of Southern California Sperm protein as a detection biomarker of early stage ovarian cancer
CN104804075A (zh) * 2014-01-24 2015-07-29 中南大学 变异的人卵透明带蛋白1和突变基因及检测方法和应用
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2016080830A2 (en) * 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
WO2020048924A1 (en) 2018-09-03 2020-03-12 Laboratoire Hra-Pharma Zp3 fragments in immunotherapy of ovarian cancer
US20250026818A1 (en) 2021-10-19 2025-01-23 Sciencemed Spóka z ograniczon odpowiedzialnoci Male contraception

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641487A (en) 1989-06-12 1997-06-24 The Government Of The United States Of America As Represented By The Secretary Department Of Health And Human Services Contraceptive vaccine based on alloimmunization with zona pellucida polypeptides
JPH0799974A (ja) * 1993-10-05 1995-04-18 Tonen Corp ヒト卵透明帯−２蛋白質をコードするｄｎａ
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US7019114B2 (en) 1998-02-19 2006-03-28 Eastern Virginia Medical School Recombinant, biologically active human zona pellucida protein 3 (HZP3) to test male fertility
US6455041B1 (en) 1998-11-17 2002-09-24 Bonita S. Dunbar Immunogenic epitopes of the human zona pellucida protein (ZP1)
AU5909500A (en) 1999-07-01 2001-01-22 University Of Georgia Research Foundation, Inc., The Method and composition for affecting reproductive systems
US6455941B1 (en) 2001-01-03 2002-09-24 Advanced Semiconductor Engineering, Inc. Chip scale package
US20090252721A1 (en) * 2003-09-18 2009-10-08 Thomas Buschmann Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer

Also Published As

Publication number Publication date
CN101365473B (zh) 2013-04-03
CN101365473A (zh) 2009-02-11
DE602006015508D1 (de) 2010-08-26
EP1951283B1 (de) 2010-07-14
PL1951283T3 (pl) 2010-12-31
EP1951283A1 (de) 2008-08-06
US20090060931A1 (en) 2009-03-05
CA2630175C (en) 2018-10-23
WO2007058536A1 (en) 2007-05-24
CA2630175A1 (en) 2007-05-24
US7968514B2 (en) 2011-06-28

Similar Documents

Publication Publication Date Title
ZA202002094B (en) Trispecific proteins and methods of use
MX2022015040A (es) Proteina espicular (s) del coronavirus geneticamente manipulada y metodos de uso de la misma.
MX2009012650A (es) Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
PH12022550693A1 (en) Multi-specific binding proteins for cancer treatment
WO2006081826A3 (en) Survivin peptide vaccine
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX342291B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
ATE296094T1 (de) Stickstoffmonoxid bildende zusammensetzungen zur behandlung von nagelbettinfektionen
BR112016002753A2 (pt) anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
WO2014111458A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
EA201200515A1 (ru) Полипептиды и их применение
MX391136B (es) FRAGMENTOS DE OspA ESTABILIZADOS CON CISTEÍNA Y MÉTODO DE USO
PH12021551656A1 (en) Pharmaceutical delivery compositions and uses thereof
NZ594268A (en) Grass peptides for vaccine
EP4406613A3 (de) Immunogene arginasepeptide
ATE473756T1 (de) Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs
DK1290160T3 (da) Humane Pellino-polypeptider
PH12021551372A1 (en) Human alpha-galactosidase variants
WO2012026820A3 (en) Immunotherapeutic method for treating prostate cancer
EA200801411A1 (ru) Новые адъюванты на основе конъюгатов и производных бис-ацилоксипропилцистеина и их применения в фармацевтических композициях
JOP20240233A1 (ar) بروتينات cd24 الطافرة واستخداماتها للوقاية من السرطان وعلاجه
MX2021008126A (es) Vacuna de arnm.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties